Company intelligence / Profile preview
NanoSmart Pharmaceuticals
California, United Statesnanosmartpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NanoSmart has completed targeting antibody and lipid nanoparticle platforms, secured IP, obtained multiple orphan drug designations, and initiated development of targeted nanoparticle formulations of APIs like doxorubicin and dactinomycin. No clinical trial data reported.
- Therapeutic areas
- Oncology
- Modalities
- NanoparticleLipid nanoparticle
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
SourcingLink.net (exclusive licensing for veterinary oncology and ANA-targeted doxorubicin)Kalos Therapeutics, Inc. (mentioned in combination therapy context)
Beyond the preview
Go deeper on NanoSmart Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoSmart Pharmaceuticals.